Abstract 765P
Background
Senaparib (IMP4297) is a novel, high potency PARP inhibitor and showed promising antitumor activity for advanced ovarian cancer in phase I studies. This open label, multicenter, single arm, phase II study aimed to evaluate the efficacy and safety of senaparib in pts with BRCA mutated recurrent PSOC.
Methods
Pts with germline and/or somatic BRCA mutated recurrent PSOC who had previously received ≥ 2 lines of platinum-based chemotherapy were enrolled. Senaparib 100 mg was administered orally once daily. The primary endpoint was independent review committee (IRC)-assessed objective response rate (ORR) and secondary endpoints included investigator (INV)-assessed ORR, progressive free survival (PFS), duration of response (DOR), overall survival (OS) and safety.
Results
As of 30 Jan 2023, 93 pts were enrolled. Treatment was still ongoing in 26 pts. Median age was 55 y (range 31–77), and 59%/41% pts were partially/fully platinum sensitive, with a median 2 prior systemic therapies (range 2-7). After a median follow up of 15.7 months, efficacy was assessed in 91 pts who received treatment of senaparib and ≥ 1 tumor evaluated and met the criteria for the response evaluable set. The INV-assessed confirmed ORR was 59.3% (95% CI, 48.4-69.2) and disease control rate (DCR) was 93.4% (95% CI, 86.2-97.5). Median DOR was 10.3 mo (95% CI, 8.2-12.0). Median PFS was 11.1 mo (95% CI, 8.3-13.8). Median OS was 31.6 mo (95% CI, 25.2-not reached) with 90% and 69% of 1 year and 2 years survival rate. IRC had not finished the assessment. 4% of pts discontinued treatment. The most common (≥ 20%) TEAEs were anemia (71%), decreased white blood cell count (55%), decreased platelet count (54%), decreased neutrophil count (50%), and nausea (28%). Grade ≥3 TEAEs in ≥5% of pts were anemia (42%), decreased neutrophil count (17%), decreased white blood cell count (16%), and decreased platelet count (16%). 2 pts reported fatal TEAEs, both of which were judged not related to treatment.
Conclusions
Senaparib demonstrated clinically meaningful antitumor activity and manageable safety profile in BRCA1/2 mutated recurrent PSOC. The OS was immature but seemed to be improved.
Clinical trial identification
NCT04089189.
Editorial acknowledgement
Legal entity responsible for the study
Impact Therapeutics, Inc.
Funding
Impact Therapeutics, Inc.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
638P - Stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer: Preliminary findings from a single-arm, prospective phase II trial (RIFLE)
Presenter: Yajiie Chen
Session: Poster session 11
641P - Phase I/II study of the EP4 antagonist CR6086 combined with the anti-PD-1 balstilimab in mismatch-repair-proficient and microsatellite stable (pMMR/MSS) chemorefractory metastatic colorectal cancer (mCRC)
Presenter: Filippo Pietrantonio
Session: Poster session 11
642P - A phase I dose escalation study of GCC19CART: A novel CoupledCAR therapy for subjects with metastatic colorectal cancer
Presenter: Jiuwei Cui
Session: Poster session 11
643P - A phase Ib/IIa study to assess the safety, tolerability, pharmacokinetics, and antitumor activity of YYB101, hepatocyte growth factor neutralizing humanized monoclonal antibody, in combination with irinotecan in metastatic or recurrent colorectal cancer patients (NOV110501-201)
Presenter: Yongjun Cha
Session: Poster session 11
645P - A phase Ib dose escalation study of binimetinib plus mFOLFIRI in patients with metastatic RAS mutated colorectal cancer
Presenter: Vaia Florou
Session: Poster session 11
646P - Phase Ib/II study of ompenaclid (RGX-202-01), afirst-in-class oral inhibitor of the creatine transporter SLC6A8, in combination with FOLFIRI and bevacizumab (BEV) in RAS mutated (RASm) second-line (2L) advanced/metastatic colorectal cancer (mCRC)
Presenter: Andrew Hendifar
Session: Poster session 11
647P - Patient-derived xenograft approach to explore differential responses to diet dependent on genotypic or phenotypic characteristics of colorectal cancer
Presenter: Giulia Rizzo
Session: Poster session 11